About: Asunercept

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Asunercept (INN; development code APG101) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US. It has also received by the European Medicines Agency (EMA) for the treatment of GBM.

Property Value
dbo:abstract
  • Asunercept (Entwicklungsname APG101) ist ein experimenteller Wirkstoff, der bis 2014 in der Behandlung von Glioblastoma multiforme (GBM) untersucht wurde. Eine Arzneimittelzulassung ist mit Stand Juli 2022 bislang nicht erfolgt. (de)
  • Asunercept (INN; development code APG101) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US. It has also received by the European Medicines Agency (EMA) for the treatment of GBM. (en)
dbo:casNumber
  • 1450882-18-4
dbo:fdaUniiCode
  • F333OQQ9UV
dbo:wikiPageID
  • 30160625 (xsd:integer)
dbo:wikiPageLength
  • 8250 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1108442927 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1450882 (xsd:integer)
dbp:legalStatus
  • Investigational (en)
dbp:unii
  • F333OQQ9UV (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Asunercept (Entwicklungsname APG101) ist ein experimenteller Wirkstoff, der bis 2014 in der Behandlung von Glioblastoma multiforme (GBM) untersucht wurde. Eine Arzneimittelzulassung ist mit Stand Juli 2022 bislang nicht erfolgt. (de)
  • Asunercept (INN; development code APG101) is a soluble CD95-Fc fusion protein which is in clinical development for the treatment of glioblastoma multiforme (GBM) and myelodysplastic syndromes (MDS). Asunercept has been granted orphan drug status for the treatment of GBM and MDS in the EU and the US. It has also received by the European Medicines Agency (EMA) for the treatment of GBM. (en)
rdfs:label
  • Asunercept (de)
  • Asunercept (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License